THERAPY DOSSIER · th-d73412b02385

Neomycin-loaded PSSA-MA/PVA ion-exchange nanofibre mat

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23510799 ↗2013Reported benefit

Neomycin-loaded poly(styrene sulfonic acid-co-maleic acid) (PSSA-MA)/polyvinyl alcohol (PVA) ion exchange nanofibers for wound dressing materials.

RatWoundWistarMaleTopical dressingNeomycin loaded at 0.001, 0.01 and 0.1 percent w/v initial…

Model: Acute skin wound

The neomycin-loaded nanofibre mats showed satisfactory antibacterial activity against both Gram-positive and Gram-negative bacteria and decreased acute wound size more than gauze or blank nanofibre mats during the first week after injury.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…